| ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. | |
| | |
MedLine Citation:
|
PMID: 18235039 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: The degradation of angiotensin (Ang) II by ACE2, leading to the formation of Ang 1-7, is an important step in the renin-angiotensin system (RAS) and one that is significantly altered in the diabetic kidney. This study examines the role of ACE2 in early renal changes associated with diabetes and the influence of ACE2 deficiency on ACE inhibitor-mediated renoprotection. RESEARCH DESIGN AND METHODS: Diabetes was induced by streptozotocin in male c57bl6 mice and ACE2 knockout (KO) mice. After 5 weeks of study, animals were randomized to receive the ACE inhibitor perindopril (2 mg x kg(-1) x day(-1)). Wild-type mice were further randomized to receive the selective ACE2 inhibitor MLN-4760 (10 mg x kg(-1) x day(-1)) and followed for an additional 5 weeks. Markers of renal function and injury were then assessed. RESULTS: Induction of diabetes in wild-type mice was associated with a reduction in renal ACE2 expression and decreased Ang 1-7. In diabetic mice receiving MLN-4760 and in ACE2 KO mice, diabetes-associated albuminuria was enhanced, associated with an increase in blood pressure. However, renal hypertrophy and fibrogenesis were reduced in diabetic mice with ACE2 deficiency, and hyperfiltration was attenuated. Diabetic wild-type mice treated with an ACE inhibitor experienced a reduction in albuminuria and blood pressure. These responses were attenuated in both diabetic ACE2 KO mice and diabetic mice receiving MLN-4760. However, other renoprotective and antifibrotic actions of ACE inhibition in diabetes were preserved in ACE2-deficient mice. CONCLUSIONS: The expression of ACE2 is significantly modified by diabetes, which impacts both pathogenesis of kidney disease and responsiveness to RAS blockade. These data indicate that ACE2 is a complex and site-specific modulator of diabetic kidney disease. |
| | |
Authors:
|
Chris Tikellis; Katarzyna Bialkowski; Josepha Pete; Karen Sheehy; Qui Su; Colin Johnston; Mark E Cooper; Merlin C Thomas |
Related Documents
:
|
3905189 - Effect of age on hepatocyte and soleus muscle insulin receptor binding in lean and gene... 8677269 - Effect of estrogen on hyperprolactinemia-induced glucose intolerance in shn mice. 2645089 - Influence of the beta 2-adrenergic agonist clenbuterol on insulin-stimulated lipogenesi... 12940869 - Effects of cyclo (his-pro) plus zinc on glucose metabolism in genetically diabetic obes... 19594769 - Effects of blood glucose fluctuation on skin biophysical properties, structure and anti... 8474309 - Age-related changes in hepatic and splenic insulin receptors and serum insulin and gluc... 18039179 - A role for pfk-2/fbpase-2, as distinct from fructose 2,6-bisphosphate, in regulation of... 1448829 - Insulin-induced normoglycemia improves ischemic outcome in hyperglycemic rats. 20500049 - Incretin-based therapies for type 2 diabetes mellitus: current status and future prospe... |
Publication Detail:
|
Type: Journal Article Date: 2008-01-30 |
Journal Detail:
|
Title: Diabetes Volume: 57 ISSN: 1939-327X ISO Abbreviation: Diabetes Publication Date: 2008 Apr |
Date Detail:
|
Created Date: 2008-03-31 Completed Date: 2008-04-25 Revised Date: 2011-01-18 |
Medline Journal Info:
|
Nlm Unique ID: 0372763 Medline TA: Diabetes Country: United States |
Other Details:
|
Languages: eng Pagination: 1018-25 Citation Subset: AIM; IM |
Affiliation:
|
Danielle Alberti Memorial Centre for Diabetes Complications, Baker Medical Research Institute, Melbourne, Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin-Converting Enzyme Inhibitors
/
pharmacology,
therapeutic use Animals Diabetes Mellitus, Experimental / physiopathology* Diabetes Mellitus, Type 1 / physiopathology* Diabetic Retinopathy / prevention & control* Kidney / drug effects, enzymology Male Mice Mice, Inbred C57BL Mice, Knockout Peptidyl-Dipeptidase A / deficiency, metabolism* Perindopril / pharmacology, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 82834-16-0/Perindopril; EC 3.4.15.1/Peptidyl-Dipeptidase A; EC 3.4.17.-/angiotensin converting enzyme 2 |
| Comments/Corrections | |
Erratum In:
|
Diabetes. 2011 Jan;60(1):360 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Association of NOS1AP genetic variants with QT interval duration in families from the Diabetes Heart...
Next Document: Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible prot...